D. Straus

B. Clarkson, J. Gaynor, D. Merke, 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Long-term follow-up of cardiac function in patients with Hodgkin's disease treated with mediastinal irradiation and combination chemotherapy including doxorubicin.

S. Yeh, D. Straus, C. Lamonte, 1986, Cancer treatment reports.

Human immunodeficiency virus-associated lymphomas.

D. Straus, David J. Straus, 1997, The Medical clinics of North America.

HUMAN IMMUNODEFICIENCY LYMPHOMAS VIRUS-ASSOCIATED

D. Straus, 1997 .

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier‐type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T‐cell lymphoma

A. Zelenetz, D. Mould, S. Horwitz, 2007, British journal of haematology.

Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols.

R. Mertelsmann, C. Cirrincione, D. Straus, 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recent results of multimodal therapy of gastric lymphoma

M. Shiu, D. Filippa, D. Straus, 1986, Cancer.

The non‐Hodgkin's lymphomas I. A retrospective clinical and pathologic analysis of 499 cases diagnosed between 1958 and 1969

H. Thaler, B. Clarkson, D. Filippa, 1983, Cancer.

Definitive irradiation for localized non-Hodgkin's lymphoma of breast.

Z. Fuks, Mitchell R. Smith, B. McCormick, 1989, International journal of radiation oncology, biology, physics.

Primary lymphoma of the spleen: Clinical features and outcome after splenectomy

D. Straus, John E. Kehoe, 1988, Cancer.

Localized non‐Hodgkin's lymphoma of the breast

Mitchell R. Smith, D. Straus, S. Brustein, 1987, Cancer.

Rituximab for Aggressive Non‐Hodgkin's Lymphomas Relapsing After or Refractory to Autologous Stem Cell Transplantation

A. Zelenetz, J. Teruya-Feldstein, C. Moskowitz, 2002, Cancer journal.

HIV-associated lymphomas.

D. Straus, 1997, Current oncology reports.

Incidence of infectious complications with the combination of bendamustine and an anti-CD20 monoclonal antibody*

A. Ni, D. Straus, Kristen M Sarlo, 2020, Leukemia & lymphoma.

R-CHOP-14 in patients with diffuse large B-cell lymphoma: Feasibility and preliminary efficacy

A. Zelenetz, S. Horwitz, O. O’Connor, 2005, Leukemia & lymphoma.

Granulocyte-Colony Stimulating Factor (G-CSF) May Improve Disease Outcome in Elderly Patients with Diffuse Large Cell Lymphoma (DLCL) Treated with CHOP Chemotherapy

A. Zelenetz, J. Glassman, J. Bertino, 2000, Leukemia & lymphoma.

Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas.

B. Clarkson, G. Wong, D. Straus, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lymphoma and other HIV-associated malignancies.

B. Safai, P. Myskowski, D. Straus, 1990, Journal of the American Academy of Dermatology.

Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patients.

A. Zelenetz, A. Dogan, B. Imber, 2021, Blood advances.

Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies.

A. Zelenetz, M. Perales, S. Devlin, 2020, Blood advances.

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.

A. Zelenetz, M. Perales, M. Fleisher, 2017, Blood.

Romidepsin and lenalidomide‐based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts

A. Zelenetz, J. Leonard, H. Schoder, 2021, American journal of hematology.

Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic Subtypes

J. Vose, A. Zelenetz, J. Winter, 2010, Clinical Cancer Research.

Central nervous system metastases from non-Hodgkin's lymphoma: treatment and prophylaxis.

L. Recht, H. Thaler, J. Posner, 1988, The American journal of medicine.

Treatment of stages I and II Hodgkin's disease with three different therapeutic modalities.

R. Mertelsmann, B. Clarkson, C. Cirrincione, 1986, The American journal of medicine.

Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone).

H. Thaler, B. Clarkson, K. Mayer, 1982, Blood.

Value of splenectomy in non‐Hodgkin's lymphoma

J. Daly, D. Straus, J. Decosse, 1985, Cancer.

Thyroid Lymphoma Comparison of Technetium-99 m-MIBI and Thallium-201-Chloride Uptake in Primary

S. Larson, A. Scott, L. Kostakoglu, 2006 .

Schedule of bortezomib administration may be an important determinant of single-agent activity in patients with relapsed or refractory follicular (FL) lymphoma and mantle cell lymphoma (MCL)

C. Moskowitz, O. O’Connor, P. Hamlin, 2007 .

A Phase ‘2-1-2’ study of two different doses and schedules of pralatrexate, a high affinity substrate for the reduced folate carrier (RFC-1), in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies

D. Mould, S. Horwitz, F. Sirotnak, 2007 .

Pralatrexate (10-Propargyl-10-Deazaaminopterin (PRX)), a Novel Antifolate, Effects Durable Complete Remissions (CR) in Patients with a Diversity of Drug Resistant T-Cell Lymphomas with Minimal Toxicity.

A. Zelenetz, M. Fleisher, S. Horwitz, 2005 .

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

G. Salles, A. Zelenetz, S. Horwitz, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.

R. Advani, J. Connors, K. Savage, 2021, The Lancet. Haematology.

Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven‐day continuous infusion

R. Warrell, D. Straus, C. Young, 1983, Cancer.

PET-Based Staging Reduces the Prognostic Impact of Early Disease Progression in Patients with Follicular Lymphoma

V. Seshan, A. Zelenetz, M. Federico, 2019, SSRN Electronic Journal.

Next Questions - Classical Hodgkin Lymphoma (cHL).

D. Straus, 2020, Clinical lymphoma, myeloma & leukemia.

Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failure

J. Feliciano, M. Bonafede, D. Straus, 2018, ClinicoEconomics and outcomes research : CEOR.

Second-Line Therapy with ICE Followed by High Dose Therapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Peripheral T-Cell Lymphomas: Minimal Benefit When Analyzed by Intent To Treat.

A. Zelenetz, S. Horwitz, S. Nimer, 2005 .

Epoetin alfa therapy for patients with hematologic malignancies and mild anemia.

D. Straus, 2003, Clinical lymphoma.

Epoetin alfa as a supportive measure in hematologic malignancies.

D. Straus, 2002, Seminars in hematology.

Phase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory Non–Hodgkin Lymphoma

A. Zelenetz, A. Iasonos, O. O’Connor, 2011, Clinical Cancer Research.

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

A. Zelenetz, J. Wright, O. O’Connor, 2009, British journal of haematology.

Patients with chemotherapy‐refractory mantle cell lymphoma experience high response rates and identical progression‐free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial

J. Vose, L. Gordon, A. Zelenetz, 2009, British journal of haematology.

A multicentre phase II clinical experience with the novel aza‐epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non‐Hodgkin lymphoma and mantle cell lymphoma

A. Zelenetz, M. Stubblefield, A. Colevas, 2008, British journal of haematology.

Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020.

D. Scadden, W. Wachsman, T. Spitzer, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Primary lymphoma of the liver

J. Fortner, J. Botet, M. Shiu, 1988, Cancer.

HIV-associated lymphoma: promising new results, but with toxicity.

D. Straus, 2005, Blood.

Concanavalin A-induced suppressor cell activity in Hodgkin's disease.

B. Clarkson, R. Good, D. Straus, 1980, Clinical immunology and immunopathology.

FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma.

A. Zelenetz, S. Horwitz, A. Younes, 2013, Clinical advances in hematology & oncology : H&O.

Fatal graft-versus-host disease following blood transfusion in Hodgkin's disease documented by HLA typing

R. Dinsmore, B. Clarkson, D. Straus, 1980 .

Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma.

J. Connors, L. Specht, P. Zinzani, 2018 .

Treatment of Newly Diagnosed Classical Hodgkin Lymphoma.

D. Straus, 2020, Clinical Lymphoma, Myeloma & Leukemia.

Initial Hodgkin treatment of the frail elderly.

D. Straus, 2017, Blood.

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.

R. Advani, J. Connors, J. Friedberg, 2022, The New England journal of medicine.

Atypical lymphoma with prolonged systemic remission after splenectomy. Description of three cases.

D. Straus, E. Kasdon, S. Robinson, 1974, The American journal of medicine.

Angioimmunoblastic lymphadenopathy: Clinical spectrum of disease

B. Clarkson, D. Straus, D. Bauermeister, 1981, Cancer.

Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study

G. Salles, A. Zelenetz, A. Younes, 2020 .

Lymphoblastic lymphoma in adults.

R. Mertelsmann, D. Straus, B. Koziner, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CD30 (Ki-1)-positive malignant lymphomas: clinical, immunophenotypic, histologic, and genetic characteristics and differences with Hodgkin's disease.

M. Ladanyi, D. Filippa, C. Portlock, 1996, Blood.

CD 30 ( Ki-l )-Positive Malignant Lymphomas : Clinical , Immunophenotypic , Histologic , and Genetic Characteristics and Differences With Hodgkin ’ s Disease

M. Ladanyi, Ming Sun, C. Portlock, 2002 .

Small Non-Cleaved-Cell Lymphoma (Undifferentiated Lymphoma, Burkitt's Type) in American Adults: Results with Treatment Designed for Acute Lymphoblastic Leukemia

K. Offit, B. Clarkson, G. Wong, 1991 .

Small non-cleaved-cell lymphoma (undifferentiated lymphoma, Burkitt's type) in American adults: results with treatment designed for acute lymphoblastic leukemia.

K. Offit, B. Clarkson, G. Wong, 1991, The American journal of medicine.

Acquired immune deficiency syndrome‐related pulmonary non‐Hodgkin lymphoma regressing after zidovudine therapy

J. Baselga, S. Krown, D. Filippa, 1993, Cancer.

Cell marker analysis in acute monocytic leukemias.

B. Clarkson, R. Good, F. Siegal, 1977, Blood.

Effectiveness of methyl-GAG (methylglyoxal-bis[guanylhydrazone]) in patients with advanced malignant lymphoma

D. Straus, S. Kempin, C. Young, 1981 .

Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study

R. Advani, J. Connors, J. Radford, 2018, Blood.

Prognostic Utility of Serum TARC, MDC, IL10, and Soluble CD163 Levels with Positron Emission Tomography (PET) Response-Adapted Therapy for Advanced-Stage Hodgkin Lymphoma (HL): a SWOG S0816 US Intergroup Correlative Study

Sonali M. Smith, J. Friedberg, J. Leonard, 2017 .

THE 23‐GENE GENE EXPRESSION‐BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL

R. Gascoyne, D. Scott, J. Friedberg, 2017 .

Osteonecrosis in patients with malignant lymphoma: A review of twenty‐five cases

D. Straus, M. Lacher, J. Lane, 1981, Cancer.

The eight‐drug/radiation therapy program (MOPP/ABDV/RT) for advanced Hodgkin's disease. A follow‐up report

B. Clarkson, S. Passe, J. Myers, 1980, Cancer.

Management of early stage Hodgkin's lymphoma.

D. Straus, 2006, Cancer treatment and research.

Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study.

A. LaCasce, K. Savage, P. Zinzani, 2018, Journal of Clinical Oncology.

Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach

Sonali M. Smith, A. LaCasce, J. Friedberg, 2018, Blood.

Phase II Trial of Dose-Dense R-CHOP Followed by Risk-Adapted Consolidation with Either ICE or ICE and ASCT, Based upon the Results of Biopsy Confirmed Abnormal Interim Restaging PET Scan, Improves Outcome in Patients with Advanced Stage DLBCL.

A. Zelenetz, S. Horwitz, O. O’Connor, 2006 .

Combination chemotherapy salvage of heavily pretreated patients with Hodgkin's disease: an analysis of prognostic factors in two chemotherapy trials and the literature.

B. Clarkson, S. Passe, D. Straus, 1981, Cancer treatment reports.

Semen cryopreservation and artificial insemination for Hodgkin's disease.

R. Gralla, B. Clarkson, D. Straus, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies

G. Salles, A. Zelenetz, S. Seo, 2022, Cancer Cell.

Clinical evaluation of 4-demethoxydaunorubicin in patients with advanced malignant lymphoma.

R. Warrell, D. Straus, C. Young, 1983, Cancer treatment reports.

Acupuncture for the treatment of post-chemotherapy chronic fatigue: a randomized, blinded, sham-controlled trial

M. Kris, A. Vickers, D. Sjoberg, 2013, Supportive Care in Cancer.

Hodgkin's disease presenting with rectal symptoms in a homosexual male. A case report and review of the literature.

D. Filippa, D. Straus, C. Coonley, 1984, Cancer investigation.

Autologous stem cell transplant for poor prognosis lymphoma

R. Dinsmore, B. Clarkson, B. Shank, 1985 .

CD 30 ( Kil )-Positive Malignant Lymphomas : Clinical , Immunophenotypic , Histologic , and Genetic Characteristics and Differences With Hodgkin ’ s Disease

M. Ladanyi, Daniel, C. Portlock, 2002 .

Late mortality and morbidity of patients with Hodgkin lymphoma treated in adulthood.

E. Riedel, K. Oeffinger, J. Ford, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Psychosocial functioning in survivors of Hodgkin lymphoma (HL) treated during adulthood

E. Riedel, D. Weinstock, K. Oeffinger, 2008 .

Lymphomas of the Gut

P. Sherlock, D. Straus, P. Lieberman, 1981 .

Comparison of technetium-99m-MIBI and thallium-201-chloride uptake in primary thyroid lymphoma.

S. Larson, A. Scott, L. Kostakoglu, 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia.

J. Michaeli, M. Andreeff, B. Gansbacher, 1992, Blood.

Primary thyroid lymphoma, a rare disease with a good treatment outcome

D. Straus, 2010, Journal of surgical oncology.

Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142--low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseas

M. Testa, L. Kaplan, A. Levine, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Necrobiotic xanthogranuloma associated with immunoglobulin m paraproteinemia in a patient with Waldenström macroglobulinemia.

M. Lacouture, M. Pulitzer, Y. Balagula, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cicatricial ectropion secondary to 5-fluorouracil therapy.

D. Straus, F. Mausolf, J. Mccracken, 1977, Medical and pediatric oncology.

Studies in acute leukemia. I. Antibody-dependent and spontaneous cellular cytotoxicity by leukemic blasts from patients with acute nonlymphoid leukemia.

R. Good, G. Fernandes, M. Nair, 1979, Blood.

How I treat mantle cell lymphoma.

D. Straus, 2007, Journal of oncology practice.

CHEMOTHERAPY FOR HIV-ASSOCIATED NON-HODGKIN LYMPHOMA (HIV-NHL) IN COMBINATION WITH HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IS NOT ASSOCIATED WITH EXCESSIVE TOXICITY.

L. Grochow, C. Flexner, D. Scadden, 1999 .

Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

J. V. Von Roenn, A. Tulpule, D. Northfelt, 1997, The New England journal of medicine.

Intensive chemotherapy with cyclophosphamide, doxorubicin, high‐dose methotrexate/ifosfamide, etoposide, and high‐dose cytarabine (CODOX‐M/IVAC) for human immunodeficiency virus–associated Burkitt lymphoma

A. Zelenetz, J. Teruya-Feldstein, A. Goy, 2003, Cancer.

Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.

L. Grochow, C. Flexner, D. Scadden, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of Burkitt's lymphoma in HIV-positive patients.

D. Straus, 1996, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

CT of primary lymphoma of the liver.

J. Newhouse, J. Botet, D. Filippa, 1989, AJR. American journal of roentgenology.

Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.

A. Zelenetz, C. Sima, J. Teruya-Feldstein, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Susceptibility Loci Associated with Specific and Shared Subtypes of Lymphoid Malignancies

A. Viale, A. Zelenetz, K. Offit, 2013, PLoS genetics.

Treatment of Burkitt lymphoma in adults

J. Gerecitano, D. Straus, 2006, Expert review of anticancer therapy.

Treatment of Burkitt lymphoma

D. Straus, 2006 .

Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma.

M. Czuczman, S. Larson, D. Scheinberg, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Principles of Chemotherapy in Hodgkin Lymphoma

D. Straus, P. Johnson, Peter W M Johnson, 2020, Hodgkin Lymphoma.

Abnormal flow volume loops in patients with intrathoracic Hodgkin's disease.

D. Straus, F. Sorhage, N. Vander Els, 2000, Chest.

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.

A. Zelenetz, J. Teruya-Feldstein, S. Nimer, 2004, Blood.

B. Clarkson, J. Gold, D. Straus, 1988, Cancer.

Generalized lymphadenopathy with morphologic features of Castleman's disease in an HIV‐positive man

D. Filippa, D. Straus, D. Lowenthal, 1987, Cancer.

Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease.

A. Zelenetz, A. Goy, C. Moskowitz, 2004, Blood.

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

R. Gascoyne, A. LaCasce, J. Friedberg, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ABVD vs BEACOPP escalated in advanced‐stage Hodgkin’s lymphoma: Results from a multicenter European study

C. Schmitt, S. Cuzzocrea, G. Martinelli, 2020, American journal of hematology.

A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression.

D. Scheinberg, D. Coit, L. Old, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV2) in relapsed and refractory lymphomas

J. Bertino, J. Crown, J. Kolitz, 1991, Investigational New Drugs.

Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low‐grade and intermediate‐grade non‐Hodgkin lymphoma. Results of a prospective randomized study

Z. Fuks, B. Clarkson, J. Yahalom, 1993, Cancer.

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay

V. Seshan, A. Zelenetz, E. Papaemmanuil, 2018, Blood Cancer Journal.

‘Comparison of survival in cerebral palsy between countries.’

R. Shavelle, D. Straus, S.M.D. Day, 2001, Developmental medicine and child neurology.

Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population

V. Seshan, S. Horwitz, M. Lunning, 2020, Leukemia & lymphoma.

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma

R. Advani, L. Gordon, J. Connors, 2019, Clinical Cancer Research.

On the Use of Cause-Specific Failure and Conditional Failure Probabilities: Examples from Clinical Oncology Data

Jeffrey J. Gaynor, Murray F. Brennan, E. Feuer, 1993 .

Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B‐cell lymphoma not eligible for autologous stem cell transplantation

A. Zelenetz, D. Cella, R. Elstrom, 2015, British journal of haematology.

Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation?

P. Maslak, O. Lin, O. O’Connor, 2006, Leukemia & lymphoma.

lymphoma cell transplantation for relapsed or primary refractory diffuse large B-cell Rituximab and ICE (RICE) as second-line therapy prior to autologous stem

A. Zelenetz, J. Teruya-Feldstein, S. Nimer, 2013 .

Primary mediastinal large B‐cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at memorial Sloan Kettering from 1980 to 1999

A. Zelenetz, S. Horwitz, P. Hamlin, 2005, British journal of haematology.

Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.

A. Zelenetz, J. Satagopan, S. Nimer, 2003, Blood.

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

A. Zelenetz, D. Esseltine, M. Stubblefield, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NHL‐3 protocol six‐drug combination chemotherapy for non‐hodgkin's lymphoma

B. Clarkson, H. Oettgen, D. Labriola, 1984, Cancer.

Late morbidity and mortality in patients with Hodgkin's lymphoma treated during adulthood.

E. Riedel, K. Oeffinger, J. Ford, 2015, Journal of the National Cancer Institute.

Chemotherapy f or H uman I mmunodeficiency Virus-Associated N on-Hodgkin's L ymphoma i n Combination W ith H ighly A ctive A ntiretroviral T herapy

L. Grochow, C. Flexner, D. Scadden, 2001 .

Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa‐2b (Intron‐A) for patients with cutaneous T‐cell lymphoma

T. Kuzel, S. Horwitz, M. Duvic, 2007, Cancer.

Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse

V. Seshan, A. Zelenetz, S. Horwitz, 2021, Blood Cancer Journal.

Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse

A. Zelenetz, A. Toure, S. Horwitz, 2019, Blood Cancer Journal.

Cyclophosphamide/Fludarabine (CF) is Active in the Treatment of Mantle Cell Lymphoma

A. Zelenetz, C. Moskowitz, A. Noy, 2001, Leukemia & lymphoma.

Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma.

V. Seshan, A. Zelenetz, M. Federico, 2020, European journal of cancer.

Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma.

V. Seshan, A. Zelenetz, S. Horwitz, 2020, Blood advances.

Clinical Characteristics and Outcomes of Extranodal Stage I Diffuse Large B Cell Lymphoma in The Rituximab-Era.

V. Seshan, A. Zelenetz, S. Horwitz, 2020, Blood.

Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups

V. Seshan, A. Zelenetz, S. Horwitz, 2020, Blood Cancer Journal.

Phase II biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.

M. Geyer, G. Inghirami, S. Horwitz, 2021, Blood.

THE COMBINATION OF DUVELISIB AND ROMIDEPSIN (DR) IS HIGHLY ACTIVE AGAINST RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA WITH LOW RATES OF TRANSAMINITIS: FINAL RESULTS

D. Fisher, S. Horwitz, E. Jacobsen, 2021, Hematological Oncology.

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.

J. Friedberg, J. Leonard, B. Cheson, 2018, Blood.

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.

A. LaCasce, L. Schwartz, B. Cheson, 2011, Blood.

The role of PET in lymphoma.

Y. Jhanwar, D. Straus, Yuliya S Jhanwar, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

IVAC With or Without Rituximab for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern Era.

Phuong Dao, E. Drill, D. Straus, 2021, Clinical lymphoma, myeloma & leukemia.

Interim [ 18 F ] fl uorodeoxyglucose positron emission tomography imaging in stage I – II non-bulky Hodgkin lymphoma : would using combined positron emission tomography and computed tomography criteria better predict response than each test alone ?

A. LaCasce, L. Schwartz, B. Cheson, 2012 .

Combination chemotherapy for the treatment of Hodgkin's disease in relapse

B. Clarkson, J. Myers, D. Straus, 1983, Cancer Chemotherapy and Pharmacology.

Treatment of advanced Hodgkin's disease with chemotherapy and irradiation. Controlled trial of two versus three alternating, potentially non-cross-resistant drug combinations.

R. Mertelsmann, J. Myers, D. Straus, 1984, American Journal of Medicine.

Treatment of advanced diffuse histiocytic lymphoma: An analysis of prognostic variables

B. Clarkson, S. Passe, D. Straus, 1982, Cancer.

Treatment of diffuse poorly differentiated lymphocytic lymphoma an analysis of prognostic variables

H. Thaler, B. Clarkson, A. Al-Katib, 1984, Cancer.

Osteonecrosis in patients with malignant lymphoma. A review of 31 cases

M. Rossleigh, D. Straus, Julius Smith, 1986, Cancer.

Impact of Early Response to Sequential High-dose Chemotherapy on Outcome of Patients With Advanced Myeloma and Poor Prognostic Features

D. Siegel, J. Michaeli, J. Glassman, 2002, Leukemia & lymphoma.

Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.

A. Zelenetz, J. Wright, O. O’Connor, 2004, The Journal of the National Comprehensive Cancer Network.

Non-Hodgkin's lymphomas: characteristics of long-term survivors following conservative treatment.

B. Clarkson, J. Gaynor, D. Filippa, 1987, The American journal of medicine.

Treatment of acute leukemia in relapse with 4'(9-acridinylamino) methanesulfon-m-anisidide (AMSA) in combination with cytosine arabinoside and thioguanine.

R. Mertelsmann, B. Clarkson, N. Flomenberg, 1981, Cancer clinical trials.

Multidisciplinary treatment of advanced Hodgkin's disease by an alternating chemotherapeutic regimen of MOPP/ABDV and low-dose radiation therapy restricted to originally bulky disease.

B. Clarkson, S. Passe, J. Myers, 1982, Cancer treatment reports.

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma

A. Zelenetz, M. Voss, A. Chen, 2017, Clinical Cancer Research.

Simplified prognostic indicators for AIDS-related lymphoma

D. Straus, 2006 .

Pralatrexate (PDX) Produces Durable Complete Remissions in Patients with Chemotherapy Resistant Precursor and Peripheral T-Cell Lymphomas: Results of the MSKCC Phase I/II Experience.

A. Zelenetz, D. Mould, C. Moskowitz, 2006 .

The acute monocytic leukemias: multidisciplinary studies in 45 patients.

R. Mertelsmann, H. Broxmeyer, B. Clarkson, 1980, Medicine.

A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL.

A. Zelenetz, H. Schoder, S. Devlin, 2018, Blood.

Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma

V. Seshan, G. Salles, A. Zelenetz, 2022, Blood Cancer Journal.

Quality‐of‐life and health benefits of early treatment of mild anemia

M. Czuczman, A. Tulpule, M. Testa, 2006, Cancer.

Targeting the microtubule apparatus in indolent and mantle cell lymphoma with the novel epothilone anlog BMS 247550 induces major and durable remissions in very drug resistant disease

A. Zelenetz, C. Moskowitz, O. O’Connor, 2005 .

Clinical guidelines, the politics of value, and the practice of medicine: physicians at the crossroads.

D. Straus, R. A. Cooper, 2012, Journal of oncology practice.

Defining Progression Free Survival After Multiple Lines of Therapy and Impact of Dynamic Changes in FLIPI for Multiply Relapsed Follicular Lymphoma in the Rituximab Era Treated at Memorial Sloan Kettering Cancer Center (MSKCC)

V. Seshan, A. Zelenetz, S. Horwitz, 2017 .

Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue.

A. Zelenetz, S. Horwitz, A. Younes, 2021, Blood advances.

Diffuse large cell lymphoma. Prognostic factors with treatment.

B. Clarkson, G. Wong, D. Straus, 1991, Leukemia.

S820 FRONTLINE BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE 3/4 CLASSICAL HODGKIN LYMPHOMA: 3-YEAR UPDATE OF THE ECHELON-1 STUDY

J. Connors, K. Savage, J. Radford, 2019, HemaSphere.

Chemotherapy only for localized Hodgkin lymphoma

D. Straus, 2011, Journal of internal medicine.

Brentuximab Vedotin in Advanced Hodgkin's Lymphoma. Reply.

J. Radford, S. Ansell, D. Straus, 2022, The New England journal of medicine.

Final Results of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for Elderly High Risk Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL).

A. Zelenetz, P. Mclaughlin, L. Fayad, 2010 .

toxicities and long term survival after autologous hematopoietic stem cell transplantation for older patients with relapsed refractory hodgkin lymphoma

S. Devlin, P. Hamlin, S. Giralt, 2019 .

Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma.

D. Straus, 2002, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

The treatment of advanced hodgkin's disease

B. Clarkson, D. Straus, B. Koziner, 1981, Blut.

Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting

A. Zelenetz, P. Goyal, S. Horwitz, 2023, Cancers.

Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse

A. Zelenetz, A. Toure, S. Horwitz, 2019, Blood Cancer Journal.

Gallium nitrate in the treatment of lymphoma.

D. Straus, 2003, Seminars in oncology.

First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1.

R. Advani, J. Connors, J. Friedberg, 2022, Journal of Clinical Oncology.

The effect of ABVD chemotherapy with and without mediastinal irradiation on pulmonary function and symptomsin early-stage Hodgkin's disease

D. Leung, J. Yahalom, C. Portlock, 1994 .

A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition.

J. Vose, A. Zelenetz, J. Winter, 2004 .

Strategies in the treatment of Hodgkin's disease.

D. Straus, 1986, Seminars in oncology.

A phase I study evaluating two dosing schedules of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) in patients with relapsed/refractory indolent and mantle cell lymphomas

A. Zelenetz, C. Moskowitz, O. O’Connor, 2008 .

Intervention Versus Observation: What Is the Appropriate Endpoint? Assessment of Endpoints in Patients with Advanced Stage Follicular Lymphoma Who Are Initially Observed

A. Zelenetz, S. Horwitz, A. Intlekofer, 2016 .

Treatment of anemia with erythropoietic agents in patients with hematologic malignancies.

D. Straus, 2005, Supportive cancer therapy.

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay

V. Seshan, A. Zelenetz, E. Papaemmanuil, 2018, Blood Cancer Journal.

Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma

I. Lossos, V. Seshan, A. Zelenetz, 2020 .

Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.

A. Zelenetz, A. Younes, H. Schöder, 2018 .

A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma.

A. Zelenetz, J. Leonard, S. Horwitz, 2015 .

Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

A. Zelenetz, S. Horwitz, A. Intlekofer, 2020 .

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)

J. Burke, N. Bartlett, H. Prince, 2022, Blood.

Initial clinical trial of a selective retinoid X receptor ligand, LGD1069.

M. Kris, R. Warrell, V. Miller, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2

R. Advani, A. Zelenetz, J. Friedberg, 2022, Blood.

Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy.

B. Clarkson, J. Gaynor, D. Merke, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Plasmacytoma and the acquired immunodeficiency syndrome.

D. Straus, B. Koziner, A. Israel, 1983, Annals of internal medicine.

CD5-Positive Marginal Zone Lymphoma: Clinical Characteristics of the MSKCC Cohort, and Comparison with the CD5-Negative Population

A. Zelenetz, S. Horwitz, A. Dogan, 2020 .

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.

A. Zelenetz, J. Bertino, J. Bertino, 2001, Blood.

Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomes

A. Zelenetz, S. Horwitz, A. Younes, 2023, Haematologica.

The Treatment of Non-Hodgkin's Lymphomas

D. Straus, 2023, Revista Brasileira de Cancerologia.

Autologous bone marrow transplantation for patients with poor-prognosis lymphoma.

B. Shank, I. Cunningham, H. Castro-Malaspina, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effectiveness of methyl-GAG (methylglyoxal-bis[guanylhydrazone]) in patients with advanced malignant lymphoma.

R. Warrell, D. Straus, S. Kempin, 1981, Blood.

Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.

A. Zelenetz, A. Dogan, A. Younes, 2023, Haematologica.

Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease.

P. Maslak, Z. Fuks, J. Yahalom, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of survival in cerebral palsy between countries.

S. Day, R. Shavelle, D. Straus, 2001 .

Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study

V. Seshan, A. Zelenetz, A. Dogan, 2023, Leukemia and Lymphoma.

THE TREATMENT OF IMON-HODGKIIM'S LYMPHOMAS

D. Straus, 2022 .

T-Cell and B-Cell Non-Hodgkin ’ s Lymphoma Revisited : Therapeutic Paradigms and Advances 1 Introduction

R. Gascoyne, P. Zinzani, S. Rosen, 2009 .

Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic Subtypes

J. Vose, A. Zelenetz, J. Winter, 2010, Clinical Cancer Research.

Positron-emission tomography e based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma

V. Seshan, A. Zelenetz, M. Federico, 2020 .

Retrospective characterization of nodal marginal zone lymphoma

A. Zelenetz, S. Horwitz, A. Intlekofer, 2023, Blood advances.

The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma

A. Zelenetz, J. Glassman, J. Bertino, 1999, Bone Marrow Transplantation.

Prospective Study of 3′-Deoxy-3′-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma

A. Zelenetz, S. Larson, S. Horwitz, 2016, The Journal of Nuclear Medicine.

High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma

A. Zelenetz, S. Horwitz, A. Intlekofer, 2019, Blood.